In a recent study, researchers demonstrated that Z526, a novel dithiocarbamate-like compound, mitigates cancer-associated cachexia (CAC) both in vitro and in vivo.
Advancement of next-generation APJ agonists with discontinuation of azelaprag Nomination of NLRP3 inhibitor BGE-102 as a development candidate, with initial Ph1 clinical data anticipated by end of 202 ...
BioAge has also entered a strategic collaboration with Lilly ExploR&D (part of Lilly Catalyze360) to discover two therapeutic antibodies that address novel metabolic aging targets identified by BioAge ...